30 June 2024 Preliminary Financial Report

Argent Biopharma Limited
30 August 2024
 

 

30 August 2024

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

 

30 June 2024 Preliminary Financial Report

 

Argent BioPharma, an innovative multidisciplinary drug discovery company within the biopharmaceutical sector, advises that is has released its 30 June 2024, Preliminary Financial Report, an unaudited Full Year Financial Report required under the Australian Securities Exchange's Listing Rules.

 

A copy of which can be found at the following URL:

 

https://www.investi.com.au/api/announcements/rgt/ba7eeb34-10e.pdf

 

-Ends-

 

Authorised for release by the board of directors, for further information please contact:

 

Argent BioPharma

Roby Zomer

CEO & Managing Director

+61 8 6555 2950

info@argentbiopharma.com

 

Argent BioPharma

Rowan Harland

Company Secretary

+61 8 6555 2950

info@argentbiopharma.com

 

 

 


 

About Argent BioPharma

Argent BioPharma Limited (the Company) (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector.  The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the Central nervous system (CNS) and Immunology treatments.

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings